Location History:
- Lavallois Perret, FR (1993 - 1994)
- Bishops Stortford, GB (1994)
Company Filing History:
Years Active: 1993-1994
Title: **David C. Billington: Innovator in Antipsychotic Agents**
Introduction
David C. Billington is an accomplished inventor based in Lavallois Perret, France, recognized for his significant contributions to the field of psychiatric medication. With a total of four patents to his name, he has focused on developing innovative compounds that show promise in treating psychiatric disorders.
Latest Patents
Among his latest inventions, Billington's patents include a class of spirocyclic antipsychotic agents. These spirocyclic piperidine derivatives act as selective ligands at sigma recognition sites, offering potential benefits in the treatment and prevention of various psychiatric disorders. The compounds he has claimed are expressed in a specific chemical structure, designed for optimized efficacy. Additionally, he has developed octahydrobenzisoquinoline derivatives, which are another class of compounds that serve as antipsychotic agents. These compounds, along with their pharmaceutically acceptable salts, are characterized by a defined formula, showcasing Billington's innovative approach to drug design.
Career Highlights
In his professional journey, David C. Billington has worked with renowned companies such as Merck Sharp & Dohme Corporation and Merck Sharpe & Dohme Corp. These experiences have enabled him to apply his expertise and further his research in the pharmaceutical industry, driving advancements in psychotropic medications.
Collaborations
Throughout his career, Billington has collaborated with several notable colleagues, including Mark Stewart Chambers and Michael Geoffrey Russell. These partnerships have been instrumental in fostering a dynamic research environment, allowing for the exchange of ideas and collaboration on projects that address complex psychiatric challenges.
Conclusion
David C. Billington’s innovative contributions to the field of antipsychotic agents underscore his commitment to enhancing psychiatric care. Through his patents and collaborations, he continues to play a pivotal role in developing solutions that impact mental health treatment, demonstrating the vital importance of research and innovation in the pharmaceutical domain.